Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed

Black Diamond Therapeutics, Inc.

2022-Q1 EPS reported -$0.70

Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).
Cash, equivalents, investments $179.7M; net cash used in ops $28.6M for Q1.
First patient dosed April 2022 in Phase 1 for BDTX-1535 (EGFR inhibitor, GBM/NSCLC); clinical update in 2023.
BDTX-4933 IND submission expected H1 2023; FGFR program candidate nomination in 2022.
Reduced workforce ~30% in April 2022; cash runway extended into Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.